01.06.2022 - SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) - PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard that has the .
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update - read this article along with other careers information, tips and advice on BioSpace
13.05.2022 - BUILDING A SOLID BASE OF VAZALORE USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted .